Vaxart, Inc.
- Close
- Oct 21, 2026
- Market cap
- $116.98M
- 243.7M shares
- Filings
- 1,022
Q3 2026+726.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q1 2026N/M FY25 yoy
Q3 2026+113.3% FY25 yoy
- $116.98M
- 4.0×
- 0.6×
- 1.8×
- 27.33%
- —
Twelve months to Sep 30, 2026 · derived
Price
Oct 21, 2026 · Official close
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $237,258,000 | reported | |
| FY 2024 | 2024-12-31 | $28,700,000 | reported | |
| FY 2023 | 2023-12-31 | $7,379,000 | reported | |
| FY 2022 | 2022-12-31 | $107,000 | reported | |
| FY 2021 | 2021-12-31 | $892,000 | reported | |
| FY 2020 | 2020-12-31 | $4,046,000 | reported | |
| FY 2019 | 2019-12-31 | $9,862,000 | reported | |
| FY 2018 | 2018-12-31 | $4,159,000 | reported | |
| FY 2017 | 2017-12-31 | $5,839,000 | reported | |
| FY 2016 | 2016-06-30 | $9,300,000 | reported | |
| FY 2015 | 2015-06-30 | $24,600,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2012 | — | $400.00K | $400.00K | — | 22.71M sh | −47.0% | — |
| FY2011 | — | $700.00K | $700.00K | — | 42.89M sh | — | — |
| FY2010 | — | $42.77M | $42.77M | — | — | — | 107.5% |
| FY2009 | — | $7.94M | $7.94M | — | — | — | 127.8% |
Segments
Products
LineFY2024ShareChange
Grant$0.00—−100.0%
Customer Service Contracts———
Government Contract———
Non Cash Royalty Revenue———
Royalty———
Total$28.70M
Biological products, except diagnostic substances
Vaxart, Inc. is the 22nd largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
IMCRImmunocore Holdings plc$400.0M29.0%8.9%$1.6BKRYSKrystal Biotech, Inc.$389.1M33.9%52.6%$9.1BADPTAdaptive Biotechnologies Corp$277.0M54.8%21.5%$4.8BVCELVericel Corp$276.3M16.5%6.0%$2.9BIOVAIovance Biotherapeutics, Inc.$263.5M60.6%148.4%$3.5B
VXRTVaxart, Inc. (this company)$237.3M726.7%6.9%$117.0M
RGNXRegenxbio Inc.$170.4M104.5%113.8%$531.0MDNAGinkgo Bioworks Holdings, Inc.$170.2M25.1%183.8%$658.8MBEAMBeam Therapeutics Inc.$139.7M120.0%57.2%$2.5BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Vaxart, Inc. · CIK 72444 · Engraved from SEC EDGAR